Sanford C. Bernstein
https://www.bernsteinresearch.comSanford C. Bernstein, a division of AllianceBernstein, is a research firm.
View Older Stories View More Recent Stories
-
Open Casting Call for Steven Spielberg’s New Version of “West Side Story”
-
UPDATE: Bernstein Upgrades Intel (INTC) to Market Perform
-
Form 497 BERNSTEIN SANFORD C FUND
-
Form 497 BERNSTEIN SANFORD C FUND
-
Form 497 BERNSTEIN SANFORD C FUND
-
Form 497 BERNSTEIN SANFORD C FUND
-
Musk's 'no new capital' promise faces scrutiny when Tesla reports results
-
Bernstein Remains Sidelined on Advanced Micro Devices (AMD) Following Strong 1Q
-
Anthem (ANTM) PT Raised to $332 at Bernstein, Remains Top Pick
-
C.H. Robinson Worldwide (CHRW) PT Raised to $90 at Bernstein
-
United Technologies (UTX) PT Lowered to $142 at Bernstein
-
Apple (AAPL) iPhone Unit Sales Estimate, EPS Estimate Cut at Bernstein
-
AllianceBernstein Holding L.P. Announces First Quarter Results
-
Clorox to Present at 34th Annual Bernstein Strategic Decisions Conference
-
Addepar Surpasses $1 Trillion in Assets on Its Platform
-
Associated Announces Annual Meeting Results, Dividends and Share Repurchase Program
-
Baton Rouge Mayor Sharon Weston Broome and Louisiana Economic Development Secretary Don Pierson Attending New Cybersecurity Office Opening in Louisiana
-
Washington, DC Shows its Power and Walks to End Lupus Now® May 12th on the National Mall
-
Amazon Renews Prime Original, Tom Clancy’s Jack Ryan, for Second Season on Prime Video Ahead of August 31 Global Series Debut, from Paramount Television, Skydance Television and Platinum Dunes
-
Manatt Announces Expansion of Healthcare Practice
-
Melanoma Research Alliance Announces $11.8 Million in 28 New Grants to Advance Melanoma Research
-
Corning Reports First-Quarter 2018 Financial Results and Continued Progress on Strategy and Capital Allocation Framework
-
Argo Group to Transfer Listing to NYSE from NASDAQ
-
European shares supported by financials; UBS disappoints
-
Hortonworks to Participate in Upcoming Second Quarter 2018 Investor Conferences
-
CORRECTING and REPLACING Investor Group Nominates Slate of Highly Qualified Director Candidates to Board of Destination Maternity
-
Investor Group Nominates Slate of Highly Qualified Director Candidates to Board of Destination Maternity
-
Limited Edition Skechers D’Lites & Toei Animation One Piece Collection to Launch in Europe
-
Bel Will Report First Quarter 2018 Results on May 3, 2018
-
Bernstein Upgrades Darden Restaurants (DRI) to Outperform
-
Research Affiliates Expands European Footprint as Head of Equity Research Moves to the Firm’s London Office
-
P&G's vitamin boost could signal more to come
-
Greenbacker Continues to Expand Its Administrative Services Team with Renewable Energy Veterans
-
JPMorgan Chase to Present at the Bernstein Strategic Decisions Conference
-
XpresSpa Group President Ed Jankowski to replace Andrew Perlman as CEO
-
OSG Billing Services Acquires Paybox
-
Milestone Movie Musical 'West Side Story' Returns to Cinemas Two Days Only, June 24 and 27, as Yearlong TCM Big Screen Classics Series Expands
-
Shire rejects $63 billion Takeda bid as Allergan drops pursuit
-
Mastercard to Participate in Upcoming Investor Conferences
-
IBM (IBM) PT Maintained at $150 at Bernstein on 1Q Report; 'Revenue Growth Elusive... Despite Strong Set of Tailwinds'
-
Winners of 2018 Ezra Jack Keats Bookmaking Competition Announced By Ezra Jack Keats Foundation and New York City Department of Education
-
Sanofi-Aventis (SNY) PT Lowered to $44 at Bernstein
-
Roche (RHHBY) PT Lowered to $33 at Bernstein
-
Pfizer (PFE) PT Lowered to $41 at Bernstein
-
Novartis (NVS) PT Lowered to $94 at Bernstein
-
Merck (MRK) PT Lowered to $67 at Bernstein
-
GlaxoSmithKline (GSK) PT Raised to $45 at Bernstein
-
Eli Lilly (LLY) PT Lowered to $88 at Bernstein
-
Bristol-Myers Squibb Co. (BMY) PT Lowered to $56 at Bernstein
-
AstraZeneca (AZN) PT Lowered to $41 at Bernstein

